ALMR vs TECH: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TECH is the larger of the two ($11.43B market cap): the incumbent the market prices for continued execution (31.48x forward earnings, beta 1.27). ALMR is the smaller challenger ($2.18B), priced similarly on forward earnings (-41.92x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ALMR vs TECH: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALMR | TECH | What it tells you |
|---|---|---|---|
| Market cap | $2.18B | $11.43B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -41.92 | 31.48 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 60% of range | 100% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.16 | 5.28 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ALMR and TECH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALMR and TECH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALMR and TECH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alamar Biosciences (ALMR) do?
Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.
What does Bio-Techne Corporation (TECH) do?
Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota. It supplies the reagents, proteins, antibodies, immunoassays, and analytical instruments that biopharma and academic researchers use in drug discovery, cell and gene therapy, and diagnostics. The portfolio spans three customer-facing brands (R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics) and is reported in two segments: Protein Sciences, the larger piece at roughly three-quarters of revenue, and Diagnostics and Spatial Biology, roughly the remaining quarter. Because it sells the consumables and instruments that sit upstream of research and manufacturing, Bio-Techne's results track biopharma and academic funding cycles rather than any single end product, with growth pockets in GMP proteins for cell therapy and its COMET spatial-biology platform.
ALMR vs TECH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALMR drivers: Consumable pull-through per instrument; Installed base expansion.
- TECH drivers: Pending Merck KGaA acquisition; Spatial biology and higher-value platforms.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. For TECH, the central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from objections in a remaining regulatory review or a change in conditions; the shareholder vote and US HSR waiting period are already behind it) could send shares back toward pre-announcement levels, while the upside above the deal price is limited.
ALMR or TECH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALMR if you believe its drivers more; TECH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALMR and TECH guides.
ALMR vs TECH: the full fundamentals
ALMR. There is no meaningful price to earnings ratio because the company loses money, so the market works off revenue multiples: about 18 times trailing sales, or roughly 13 times the 2026 guide once net cash is taken out, down from above 20 times in August. That is still a premium tools multiple for a platform growing north of 50% with widening gross margin. Five analysts carry a mean target near $35.40, and the November 3 report will show whether third-quarter revenue lands near the roughly $30.2 million consensus.
TECH. Figures are approximate as of October 16, 2026; verify live numbers and the current status of the Merck KGaA transaction before acting. Because the stock trades within about 1% of the $73 cash offer, multiples such as a trailing P/E above 60 matter far less than the merger: the remaining return is the spread to the deal price, weighed against the odds and timing of closing. If the deal completes, holders receive $73 per share in cash; if it broke, the stock would re-rate to standalone fundamentals.
Headline figures (approximate, October 2026): ALMR shows revenue (ttm) ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year, 2026 revenue guidance ~$116 million to $120 million (consensus ~$119 million), gross margin (ttm) ~59% (Q2 2026 ~60%), net loss (ttm) ~$50 million; Q2 2026 EPS ~-$0.20 vs ~-$0.32 expected; TECH shows situation Being acquired by Merck KGaA at $73 per share in cash (announced June 25, 2026); shareholders approved September 23, 2026; US HSR waiting period expired September 18, 2026, enterprise value of deal ~$11.3 billion, roughly a 36% premium to the prior one-month average price, share price and spread ~$72.45 on Oct 16, 2026, about $0.55 (under 1%) below the $73 offer, market cap ~$11.4 billion.
The bottom line: ALMR vs TECH
ALMR and TECH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALMR and TECH exposure against your real portfolio. It is not an investment adviser.
Wondering how ALMR or TECH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alamar Biosciences
Ask Walnut's AI anything about ALMR and see how it fits what you own.
FAQ
What is the difference between ALMR and TECH?
+
Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALMR or TECH the better stock?
+
Neither is universally better. TECH is the larger incumbent; ALMR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALMR or TECH?
+
On forward P/E (as of November 2026), ALMR trades at -41.92x and TECH at 31.48x, so ALMR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALMR and TECH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALMR vs TECH?
+
ALMR: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation still leaves little slack, with the shares near 18 times trailing revenue while the company loses money each quarter, and the 27% fall over the past month shows how hard a small, recently listed stock can reprice without any change in reported numbers. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which falls in mid-October 2026 and can put additional shares into a thinly traded float. The November 3 third-quarter report is the next test of the $116 million to $120 million full-year guide. TECH: The central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from objections in a remaining regulatory review or a change in conditions; the shareholder vote and US HSR waiting period are already behind it) could send shares back toward pre-announcement levels, while the upside above the deal price is limited. Timing risk matters too, since the money is tied up until the transaction completes in late 2026 or early 2027. If the deal fell through, the stock would again trade on fundamentals, where organic growth in Protein Sciences has been soft and demand depends on biotech and academic funding cycles that remain under pressure. Foreign-exchange swings, integration uncertainty for the combined entity, and the general execution risk of a large cross-border merger add further variables outside an individual investor's control.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALMR or TECH; figures are approximate and dated (as of November 2026). Verify current data before investing.